Analysts on Wall Street project that McKesson (MCK) will announce quarterly earnings of $9.81 per share in its forthcoming report, representing an increase of 58.7% year over year. Revenues are projected to reach $93.7 billion, increasing 22.7% from the same quarter last year. The current level reflects a downward revision of 1.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights. Given this perspective, it's time to examine the average forecasts of specific McKesson metrics that are routinely monitored and predicted by Wall Street analysts. Analysts expect 'Revenue- U.S. Pharmaceutical' to come in at $85.79 billion. The estimate indicates a change of +24.7% from the prior-year quarter. The consensus estimate for 'Revenue- Prescription Technology Solutions' stands at $1.36 billion. The estimate suggests a change of +15.1% year over year. Analysts predict that the 'Revenue- International' will reach $3.55 billion. Analysts forecast 'Revenue- Medical-Surgical Solutions' to reach $2.79 billion. The estimate indicates a change of -1.6% from the prior-year quarter. According to the collective judgment of analysts, 'Adjusted Operating Profit- U.S. Pharmaceutical' should come in at $1.05 billion. The estimate compares to the year-ago value of $901 million. The consensus among analysts is that 'Adjusted Operating Profit- International' will reach $96.42 million. Compared to the current estimate, the company reported $94 million in the same quarter of the previous year. Analysts' assessment points toward 'Adjusted Operating Profit- Prescription Technology Solutions' reaching $267.80 million. Compared to the present estimate, the company reported $212 million in the same quarter last year. The combined assessment of analysts suggests that 'Adjusted Operating Profit- Medical-Surgical Solutions' will likely reach $283.33 million. Compared to the present estimate, the company reported $248 million in the same quarter last year. View all Key Company Metrics for McKesson here>>> Over the past month, shares of McKesson have returned +3.7% versus the Zacks S&P 500 composite's +0.4% change. Currently, MCK carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Story Continues Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
McKesson (MCK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...